Polyrizon Publishes U.S. Patent Application For Advanced Hydrogel Nasal Technologies

Polyrizon Ltd., a biotech company focused on developing groundbreaking intranasal hydrogels, announced that the United States is innovating solutions for protection and treatment through the nasal cavity. United States Patent and Trademark Office (USPTO) has published a national phase patent application for its core platform technologies. These include the Capture and Contain (C&C™) nasal blocker technology and the Trap and Target (T&T™) advanced drug delivery system, underscoring Polyrizon's dedication. 

The Capture and Contain (C&C™) platform is made with a normal 3D polymeric network that has normal interactiveness with the nasal mucosa. This advanced system behaves more as a physical barrier that effectively holds in allergens, viruses, and moulds. It thus denies the opportunity to enter the body, and besides providing the best protection.

On the other hand, Trap and Target (T&T™) offer a new platform for intranasal drug delivery systems. This design causes longer stay time and better contact with mucosal layers, thus enhancing precise medication application. Created by drug delivery professionals, T&T can be easily adjusted to fit any molecule and, therefore, improve the efficiency of treatment, as well as enlarge the list of possible applications.